Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2011. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by eight individuals on February 9, 2011, at a price of £11.75 per share through the Company's Share Reward Plan. Each individual acquired 11 shares under the partnership element (personal contribution) and 11 shares under the matching element (Company contribution), except for Dr. P J T Vallance, whose order of acquisition is listed differently but totals the same amount. The individuals involved are Mr. A P Witty, Mr. J S Heslop, Mr. S M Bicknell, Mr. E J Gray, Mr. D S Redfern, Ms. C Thomas, Dr. P J T Vallance, and Mrs. V A Whyte.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of share purchases in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of £11.75 per Ordinary share on February 9, 2011.
- Confirm the total number of shares acquired by each executive (22 shares per person: 11 personal, 11 company match).
- Review the full list of participating Directors and Persons Discharging Managerial Responsibility.
- Note that this filing does not contain financial results; refer to Form 20-F for comprehensive financial data.